Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Differentiation therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    217 result(s) found for: Differentiation therapy. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000155-14 Sponsor Protocol Number: V2.0 Start Date*: 2013-12-13
    Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II
    Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003893-17 Sponsor Protocol Number: SAKK36/13 Start Date*: 2017-11-23
    Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research
    Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
    Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012807-25 Sponsor Protocol Number: IIL-MCL0208 Start Date*: 2010-01-28
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A...
    Medical condition: Mantel cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005573-21 Sponsor Protocol Number: GLIOMARK1 Start Date*: 2016-04-26
    Sponsor Name:pro-ACTINA S.A.
    Full Title: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis
    Medical condition: Patients with high grade brain tumors
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006208-21 Sponsor Protocol Number: ELKE-2006 Start Date*: 2006-10-23
    Sponsor Name:Department of Dermatology, University of Kiel
    Full Title: Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and diff...
    Medical condition: Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001108-19 Sponsor Protocol Number: SAKK 36/06 Start Date*: 2008-09-23
    Sponsor Name:SAKK
    Full Title: Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol S...
    Medical condition: Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015909-39 Sponsor Protocol Number: INT5909 Start Date*: 2009-12-02
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly
    Medical condition: Mantle-cell lymphoma (MCL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011433-27 Sponsor Protocol Number: ML22489 Start Date*: 2009-11-04
    Sponsor Name:Roche Romania SRL
    Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003601-10 Sponsor Protocol Number: NL69300 Start Date*: 2020-09-18
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: Treatment of Skin Severity in Ichthyosis with Hyperbaric Oxygen Therapy
    Medical condition: ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10021198 Ichthyosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003385-24 Sponsor Protocol Number: 2815 Start Date*: 2016-09-28
    Sponsor Name:GGZ inGeest, parner VUmc
    Full Title: The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial
    Medical condition: Interictal delirium during electric convulsive therapy- course
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005541-36 Sponsor Protocol Number: NLG-MCL6 Start Date*: 2014-11-27
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.
    Medical condition: Relapsed/refractory mantle cell lymphoma,
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000711-88 Sponsor Protocol Number: PCI-32765MCL2001 Start Date*: 2012-09-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progres...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004093-27 Sponsor Protocol Number: ML20493 Start Date*: 2007-04-04
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma.
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-002935-30 Sponsor Protocol Number: 20-01434 Start Date*: 2023-01-20
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001430-16 Sponsor Protocol Number: 3066K1-305-WW Start Date*: 2005-04-20
    Sponsor Name:Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development
    Full Title: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006177-32 Sponsor Protocol Number: CC-5013-MCL-003 Start Date*: 2010-01-06
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA
    Medical condition: Mantle-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) FR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000540-25 Sponsor Protocol Number: FIL_KLIMT Start Date*: 2019-06-25
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study
    Medical condition: BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007756-34 Sponsor Protocol Number: CC-5013-MCL-001 Start Date*: 2009-02-06
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent lenalidomide (Revlimid ®) in patients with mantle cell NHL who have relapsed or progressed ...
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 23:15:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA